EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost lymphoma treatment
Disease control Recruiting nowThis phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC